UNSPSC 51162002: Albuterol/ipratropium

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162002 Albuterol/ipratropium is a Commodity code nominally designating a specific respiratory medication combination, but recent state and local procurement activity under this code does not reflect pharmaceutical procurement aligned with the code's name. The two recent solicitations tagged to this code instead involve naloxone procurement and on-site pharmacy services delivery — neither of which matches the respiratory-therapy drug scope the code nominally describes. Seminole County, Florida issued an IFB for naloxone and safe drug deactivation systems (1,900 units and 800 units annually, respectively), while Hall County, Georgia issued an RFQ/P for comprehensive on-site pharmacy services at a county health center clinic serving approximately 3,005 eligible individuals across multiple insurance plans. The mismatch suggests either a coding error in how these opportunities were tagged at the source or a data-entry artifact; the code shows little relevant recent activity aligned with its actual pharmaceutical scope.

Geographic activity is limited to Florida and Georgia based on the two posted opportunities. Seminole County's naloxone procurement (IFB 60459723LAS, due July 26, 2023) specified quarterly deliveries to the Seminole County Community Health Building in Sanford and included a two-year initial term with one-year renewal option, with vendors responsible for all shipping and delivery costs. Hall County's pharmacy services RFQ/P (#47-010, due June 4, 2026) sought a single vendor to stock and dispense a formulary of 25 medications, with scoring weighted 80% for technical qualifications and 20% for cost, and a one-year initial term beginning January 1, 2027, with four optional one-year renewals. Neither solicitation specified set-aside designations for disadvantaged enterprises. The code appears to generate minimal matching procurement activity; business development professionals should verify whether their actual service or product line aligns with respiratory-therapy combination drugs before pursuing opportunities tagged under this code.